Grace Therapeutics, Inc.: goodwill carrying amount
Goodwill carrying amount for Grace Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Grace Therapeutics, Inc. financial histories
What this measure means
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
Exact concept: us-gaap:Goodwill. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-03-31 to 2026-03-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2026-03-31 | 8,138,000 | USD | 2026-06-18 | 10-K · 0001140361-26-025662 |
| At date | 2025-03-31 | 8,138,000 | USD | 2026-06-18 | 10-K · 0001140361-26-025662 |
| At date | 2024-03-31 | 8,138,000 | USD | 2026-06-18 | 10-K · 0001140361-26-025662 |
| At date | 2023-03-31 | 8,138,000 | USD | 2025-06-23 | 10-K · 0001140361-25-023259 |
| At date | 2022-03-31 | 12,964,000 | USD | 2024-06-21 | 10-K · 0000950170-24-075875 |
Related financial histories
- Grace Therapeutics, Inc.: total assets
- Grace Therapeutics, Inc.: total liabilities
- Grace Therapeutics, Inc.: stockholders equity
- Grace Therapeutics, Inc.: cash and cash equivalents
- Grace Therapeutics, Inc.: net income or loss
- Grace Therapeutics, Inc.: operating cash flow
- Grace Therapeutics, Inc.: financing cash flow
- Grace Therapeutics, Inc.: investing cash flow
- Grace Therapeutics, Inc.: retained earnings or deficit
- Grace Therapeutics, Inc.: basic weighted-average shares
- Grace Therapeutics, Inc.: diluted weighted-average shares
- Grace Therapeutics, Inc.: basic earnings per share
- Grace Therapeutics, Inc.: diluted earnings per share
- Grace Therapeutics, Inc.: income tax expense or benefit
- Grace Therapeutics, Inc.: net property, plant and equipment
- Grace Therapeutics, Inc.: share-based compensation expense
- Grace Therapeutics, Inc.: operating income or loss
- Grace Therapeutics, Inc.: current assets
- Grace Therapeutics, Inc.: current liabilities
- Grace Therapeutics, Inc.: net finite-lived intangible assets
- Grace Therapeutics, Inc.: net current accounts receivable
- Grace Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Grace Therapeutics, Inc. / CIK 0001444192
- Captured
- 2026-09-20T09:04:24.067Z
- SEC response SHA-256
5b69cc68942ac99439db286c3fb40eff559eb7df0ecb4af9a3f0c1a7f9246502
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001444192.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))